Alpha-Synuclein Overexpressing Neurons <table class="infobox infobox-cell">Category </td>Location </td>Cell Types </td>Primary Neurotransmitter </td>Key Markers </td>
Introduction ...
Alpha-Synuclein Overexpressing Neurons <table class="infobox infobox-cell">Category </td>Location </td>Cell Types </td>Primary Neurotransmitter </td>Key Markers </td>
Introduction Alpha-synuclein overexpressing neurons are disease model neurons that overexpress the SNCA gene encoding the alpha-synuclein protein. These models replicate the proteinaceous inclusions known as Lewy bodies and Lewy neurites, which are pathological hallmarks of Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). These neurons are typically generated through viral vector-mediated gene delivery or derived from iPSCs carrying SNCA duplication/triplication mutations. [@spillantini1997]
Overview
Mermaid diagram (expand to render)
Multi-Taxonomy Classification
Taxonomy Database Cross-References
PanglaoDB Marker Cross-References
External Database Links
[Cell Ontology (CL:0004117)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0004117)
[OBO Foundry (CL:0004117)](http://purl.obolibrary.org/obo/CL_0004117)
[Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
[CellxGene Census](https://cellxgene.cziscience.com/)
[Human Cell Atlas](https://www.humancellatlas.org/)
[PanglaoDB](https://panglaodb.se/)
Taxonomy & Classification
PanglaoDB Marker Cross-References
External Database Links
[Cell Ontology (CL:0004117)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0004117)
[OBO Foundry (CL:0004117)](http://purl.obolibrary.org/obo/CL_0004117)
[Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
[CellxGene Census](https://cellxgene.cziscience.com/)
[PanglaoDB](https://panglaodb.se/)
Alpha-Synuclein Biology
Normal Protein Function Alpha-synuclein is a 140-amino acid protein predominantly expressed in presynaptic terminals. Its normal functions include:
Synaptic vesicle regulation : Modulates synaptic vesicle pools and releaseDopamine synthesis : Influences tyrosine hydroxylase activityChaperone activity : Involved in protein folding homeostasisMembrane binding : Associates with synaptic vesiclesPathological Aggregation In disease states, alpha-synuclein undergoes:
Misfolding : Conformational change from alpha-helix to beta-sheetOligomerization : Formation of toxic soluble oligomersFibrillization : Aggregation into insoluble fibrilsInclusion formation : Lewy body and Lewy neurite development
SNCA Mutations and Copy Number Variants
A53T (SNCA^A53T) : Early-onset familial PDA30P (SNCA^A30P) : Reduced membrane bindingE46K (SNCA^E46K) : Increased aggregationSNCA duplication : Sporadic PD risk factorSNCA triplication : Parkinsoid syndrome (Dementia-Parkinsonism)Cellular Phenotypes
Protein Aggregation
Lewy body-like inclusions : Cytoplasmic aggregatesLewy neurites : Axonal and dendritic inclusionsPhospho-Ser129 alpha-synuclein : Pathological phosphorylationUbiquitin-positive aggregates : Proteostasis impairmentSynaptic Dysfunction
Reduced synaptic vesicle number : Depleted vesicle poolsImpaired dopamine release : Synaptic transmission deficitsSynaptic protein loss : Synaptophysin reductionNeuronal connectivity deficits : Reduced dendritic branchingMitochondrial Dysfunction
Complex I impairment : Electron transport chain defectsMitochondrial fragmentation : Altered dynamicsReduced ATP production : Bioenergetic failureIncreased mitochondrial ROS : Oxidative stressProteostasis Impairment
Lysosomal dysfunction : Reduced autophagic clearanceER stress : Unfolded protein response activationProteasomal inhibition : Impaired protein degradationAggregate seeding : Spreading pathologyMechanisms of Neurodegeneration
Toxic Oligomer Hypothesis Soluble oligomeric forms of alpha-synuclein are considered the most toxic species:
Membrane pore formation : Causing ion dysregulationMitochondrial damage : Direct interaction with mitochondriaSynaptic dysfunction : Presynaptic terminal impairmentSpread prion-like behavior : Intercellular propagationPrion-Like Propagation Alpha-synuclein pathology can spread via:
Release : Secretion from affected neuronsUptake : Internalization by neighboring cellsTemplate-directed misfolding : Inducing endogenous protein aggregationNetwork spread : Connectome-dependent propagation
Inflammation
Microglial activation : Enhanced by extracellular alpha-synucleinCytokine release : IL-1β, TNF-α, IL-6 elevationOxidative stress : NADPH oxidase activationNeuronal damage amplification : Inflammatory cascadeFunction
Protein aggregation modeling : Lewy body formationSynaptic dysfunction studies : Dopamine release impairmentPrion-like spreading : Pathology propagation mechanismsTherapeutic target validation : Oligomer and aggregation inhibitorsClinical Relevance
Disease Modeling Alpha-synuclein overexpressing neurons enable study of:
Sporadic and familial PD mechanisms
Lewy body dementia pathology
Multiple system atrophy progression
Therapeutic intervention effects
Therapeutic Strategies
Aggregation Inhibitors
Small molecule inhibitors : E.g., Anle138b, CLR01Antibody therapies : Anti-alpha-synuclein antibodiesMolecular tweezers : CLR01 (molecular disruptor)Clearance Enhancement
Autophagy enhancers : Rapamycin, TrehaloseLysosomal activators : GBA gene therapyImmunotherapies : Active and passive vaccinationNeuroprotective Approaches
Antioxidants : MitoQ, N-acetylcysteineGlutamate antagonists : NMDA receptor modulatorsGrowth factors : GDNF, BDNFResearch Applications
These models enable:
High-throughput screening for aggregation inhibitors
Target engagement studies
Mechanism of action determination
Biomarker development
Biomarkers
Phospho-Ser129 : Pathological alpha-synuclein markerTotal alpha-synuclein : CSF and blood biomarkerOligomeric alpha-synuclein : Toxic species detectionNeurofilament light chain : Neurodegeneration marker[Alpha-Synuclein](/proteins/alpha-synuclein) SNCA Gene
[Parkinson's Disease](/diseases/parkinsons-disease)
[Dementia with Lewy Bodies](/diseases/lewy-body-dementia)
Dopamine Neurons
Lewy Bodies
Background The study of Alpha Synuclein Overexpressing Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
External Links
[Michael J. Fox Foundation - Alpha-Synuclein Research](https://www.michaeljfox.org/)
[Lewy Body Dementia Association](https://www.lbda.org/)
[Parkinson's Foundation - Alpha-Synuclein](https://www.parkinson.org/)
[NCBI Gene - SNCA](https://www.ncbi.nlm.nih.gov/gene/6622)
Show full description